{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:39:06Z","timestamp":1790995146083,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jacc.2025.04.049","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:07:47Z","timestamp":1746436067000},"page":"196-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD"],"prefix":"10.1016","volume":"86","author":[{"given":"Pam R.","family":"Taub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donavon","family":"Wewers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Garcia Cantu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Deck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lesogor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Mena-Madrazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.04.049_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2025.04.049_bib2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.04.049_bib3","article-title":"PCSK9 and lipid metabolism: genetic variants, current therapies, and cardiovascular outcomes","author":"Grejtakova","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2025.04.049_bib4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1210\/clinem\/dgac708","article-title":"Targeting PCSK9 with antibodies and gene silencing to reduce LDL cholesterol","volume":"108","author":"Newman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.04.049_bib5","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.04.049_bib6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.04.049_bib7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.04.049_bib8","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.04.049_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-016-0604-3","article-title":"Statins and their effect on PCSK9\u2014impact and clinical relevance","volume":"18","author":"Taylor","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2025.04.049_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.2997","article-title":"Inter-individual variability in LDL-C reductions with inclisiran\u2014data from ORION-10 and ORION-11","volume":"41","author":"Wright","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.04.049_bib11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","article-title":"High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2025.04.049_bib12","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.04.049_bib13","series-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.jacc.2025.04.049_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029263","article-title":"Statin use and eligibility for primary prevention of atherosclerotic cardiovascular disease among adults at borderline or intermediate risk in the United States","volume":"12","author":"Hammond","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.04.049_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007485","article-title":"Cardiovascular disease risk\u2013based statin utilization and associated outcomes in a primary prevention cohort: insights from a large health care network","volume":"14","author":"Saeed","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2025.04.049_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among US adults between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.04.049_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41598-021-03796-6","article-title":"Personalizing cholesterol treatment recommendations for primary cardiovascular disease prevention","volume":"12","author":"Sarraju","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2025.04.049_bib18","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.04.049_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.04.049_bib20","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.04.049_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201196","article-title":"Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease","volume":"14","author":"Hope","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.04.049_bib22","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.04.049_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2025.04.049_bib24","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary endpoints in ORION 1","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.04.049_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/eurheartj\/ehab532","article-title":"How to live to 100 before developing clinical coronary artery disease: a suggestion","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.04.049_bib26","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.04.049_bib27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.04.049_bib28","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.04.049_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.04.049_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.04.049_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12872-020-01566-2","article-title":"Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2025.04.049_bib32","first-page":"685","article-title":"Patterns of statin use in a real-world population of patients at high cardiovascular risk","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacc.2025.04.049_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005041","article-title":"Medication discontinuation in the IMPROVE-IT trial","volume":"12","author":"Navar","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2025.04.049_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124587","article-title":"Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Battaggia","year":"2015","journal-title":"PLoS One"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725063922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725063922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:16:00Z","timestamp":1778386560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725063922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0735109725063922"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.04.049","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}